NDAINJECTIONINJECTABLE
Approved
Jul 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
MIACALCIN (calcitonin salmon) by Viatris (2) is agonist. Approved for symptomatic paget's disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase, urinary hydroxyproline excretion, postmenopausal osteoporosis in women greater than 5 years postmenopause and 3 more indications. First approved in 1986.
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIACALCIN (calcitonin salmon) is an injectable calcitonin agonist that acts primarily on bone to regulate calcium metabolism while also producing direct renal and gastrointestinal effects. It is indicated for symptomatic Paget's disease of bone, postmenopausal osteoporosis, and hypercalcemia. The drug has greater potency per mg and longer duration of action compared to mammalian-origin calcitonins.
LOE Approaching
The product is approaching loss of exclusivity with minimal current market presence ($837K spending), signaling a contracting team focused on legacy maintenance rather than growth initiatives.
Mechanism of Action
agonist. Calcitonin salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer…
Pharmacologic Class:
Calcitonin
Worked on MIACALCIN at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.